Loading...

CIPLA Cipla Ltd Contract Awards Announcement

Cpl

CPL

Cipla Ltd

(CIPLA)

2025 Announcement

Regulatory disclosure

Form 483 observations

Earnings Conference Call

Newspaper Publication

Regulatory Compliance

Board Meeting Intimation

Resignation of Director

Management Change

Share transfer window

Scheme of Amalgamation

Equity Investment

Appointment and Amalgamation

Supply disruption

Wholly Owned Subsidiary

ESG Rating Revision

Regulatory disclosure

USFDA inspection update

Regulatory disclosure

Analyst / Investor Meeting

Pre-Approval Inspection

Tax Compliance Inspection

Investor Meeting

Unaudited financial results

Conference Call Audio

Re-appointment as Independe...

Independent Director Appoin...

Investor Presentation

Q3 FY26 results

Unaudited results (standalo...

Regulatory compliance update

Lanreotide supply pause (Ph...

Earnings Call Details

USFDA inspection observations

Regulatory Update

ESG Rating Disclosure

Exclusive supply and market...

ESOP share allotment

New Product Launch

ESG Rating Disclosure

Asset Acquisition

Reg 29(2 Disclosure)

Transfer Requests Update

Earnings Call Transcript

Inzpera Acquisition

Financial Results

Earnings Call Update

Management Changes

Q2FY26 Performance

Management Change

Q2FY26 Presentation

Financial Results Approved

Financial Results

Investor Meeting

Product Launch Agreement

Compliance Certificate

Earnings Conference Call

ESG Rating Update

Investor Meeting

Acquisition Update

Saksham Niveshak Campaign

Conference Cancellation

ESG Rating Update

USFDA Inspection Update

Share Transfer Update

Clarification Issued

ESG Rating Assigned

Financial Results Publication

Earnings Call Audio

Cipla Growth Update

Investor Presentation

Annual General Meeting

Cipla Acquisition Update

Management Change

Compliance Certificate

ESG Rating Change

Earnings Call Scheduled

Share Transfer Notice

Investor Meetings

Share Allotment

Annual General Meeting

AGM Announcement

ESG Rating Update

Management Change

USFDA Inspection

Annual Compliance Report

Cipla Acquisition Update

New Subsidiary Formation

Secretarial Auditor Update

Stake Acquisition

USFDA Inspection Update

Earnings Call Summary

Financial Results Published

Earnings Call Audio

Investor Presentation

Q4 FY25 Results

Stock Options Grant

Auditor Appointments

Auditor Appointments

Investor Meetings

Investor Meeting

ESG Rating Update

USFDA Inspection Update

Earnings Call Scheduled

Compliance Certificate

USFDA Inspection

Investment Update

Investor Presentation

Investor Meetings

USFDA Inspection Update

Cipla Investment

Q3 FY25 Earnings Call

Financial Results Update

Earnings Call Recording

Management Change

Q3 FY25 Results

Investor Presentation

Management Change

USFDA Inspection

GST Penalty Imposed

Compliance Certificate

Tax Demand Reduction

Earnings Call Notice

GST Penalty Notification

GST Penalty Imposed

ESG Score Announcement

GST Penalty Notification

Director Retirement

Q2 FY25 Earnings

USFDA Inspection Update

Earnings Call Recording

Earnings Results

Investor Presentation

Q2 FY25 Results

Equity Acquisition

Regulatory Appeal Notice

Regulatory Certificate

Earnings Call Scheduled

Equity Shares Allotment

Subsidiary Acquisition

Postal Ballot Notice

Equity Shares Allotment

Management Correction

Director Retirement

GST Penalties Imposed

Annual General Meeting

GST Penalty Imposed

Management Change

Investor Meetings Scheduled

Customs Penalty Imposed

Change in Meeting Mode

Analyst/Investor Meetings

Equity Allotment

Earnings Call Transcript

Newspaper Advertisement

Management Changes

Financial Results Publication

Investor Presentation

Financial Results Announcement

Financial Results Announcement

Analyst Meetings

Announcement on Annual Gene...

Certificate Submission

USFDA Inspection

Earnings Conference Call

Employee Stock Options Allo...

Subsidiary Dissolution

Dissolution Announcement

USFDA Inspection Update

Inspection Findings Disclosure

Investment Expansion

Notice to Shareholders rega...

Tax Appeal Order

Equity Shares Allotted

Management Change

Compliance Submission

Meeting Intimation

Cipla Approval for Lanreoti...

Acquisition of Achira Labs ...

Earnings Call Transcript

Shares Sale Clarification

Management Change

Earnings Call Outcome

Financial Results Publication

Financial Decisions

Investor Presentation

Financial Results Announcement

Cost Auditor Appointment

Management Changes

Investor Meeting

Penalty Orders from GST Aut...

Penalty Imposed by GST Auth...

Penalty Imposed by GST Auth...

Acquisition Update

Penalty Imposed by GST Auth...

Certificate Submission

Notice of Postal Ballot

Compliance Certificate

Certificate Submission

Stock Allotment

Acquisition Announcement

Earnings Conference Call

Management Change

Partnership Announcement

Merger Approval

Penalty Imposed by GST Auth...

Management Change

Management Change

Employee Stock Allotment

Sale Completion

Meeting Intimation

Penalty Imposed by GST Auth...

Analyst/Investor Meeting

Business Transfer

Joint Venture Incorporation

USFDA Inspection

Allotment of ESOP/ESPS

Presentation for Analyst/In...

Acquisition Completed

Acquisition of Stake

Penalty from GST Authority

Cipla Ltd. - Transcript of ...

Earnings Conference Call

Management changes

Acquisition in Mexico

Investor Presentation

Financial Results Announcement

Financial Results Publication

Rescheduled Board Meeting

Financial Results Alert

Allotment of Equity Shares

Compliance Certificate

Financial Results and Earni...

Amendment of Agreement

Allotment of ESOP/ESPS

Penalty Imposed

Penalty Orders from GST Aut...

Penalty Imposed

Regulatory Action - Penalty...

Penalty from GST Authority

Recall - Leaking Sachets

Investment in GoApptiv

Acquisition of Stake in GoA...

Cessation of Facility Deman...

Recall Announcement

Penalty Imposed

Regulatory Action

Analyst/Investor Meetings S...

Investor Meetings

Acquisition of Stake

Clarification on Warning Le...

ESOP/ESPS Allotment

Warning Letter from USFDA

Facility Demand Guarantee

Slump Sale of Business Unde...

Earnings Conference Call Re...

Investor Presentation

Financial Results

Financial Results Publication

Certificate under Reg. 74 (...

US FDA Inspection

US FDA Inspection Update

Sale of Stake in Saba Inves...

Allotment of Equity Shares

USFDA Inspection

Allotment of ESOP/ESPS

Acquisition of Actor Pharma

Equity Offerings

Civil, Regulatory Compliance

Analyst/Investor Meetings

Financial Statements

Management Changes

Management Changes

Equity Investment

Financial Statements

Management Changes

Merger of Equals

Employee Stock Option Scheme

Meeting Announcement

Financial Statements

Conference Call

Earnings Call Transcript

Divestment of Assets

Related party transactions

Equity, Debt, VC, Private E...

Financial Results Publication

No Form 483 Observations

External Links:

Data:

Cipla inks a exclusive 5-year India agreement with Pfizer for Corex, Dolonex, Neksium, and Dalacin C, expanding its distribution and market reach.

AI Assistant

Cipla Ltd

2025

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.